Current and emerging targeted therapies for spinal muscular atrophy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and emerging targeted therapies for spinal muscular atrophy
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2023-10-16
DOI
10.1080/14737175.2023.2268276
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review of cardiac safety in onasemnogene abeparvovec gene replacement therapy: translation from preclinical to clinical findings
- (2023) Deepa H. Chand et al. GENE THERAPY
- Risdiplam in non‐sitter patients aged 16 years and older with 5q spinal muscular atrophy
- (2023) Nancy Carolina Ñungo Garzón et al. MUSCLE & NERVE
- Detect-seq, a chemical labeling and biotin pull-down approach for the unbiased and genome-wide off-target evaluation of programmable cytosine base editors
- (2023) Zhixin Lei et al. Nature Protocols
- A spinal muscular atrophy modifier implicates the SMN protein in SNARE complex assembly at neuromuscular synapses
- (2023) Jeong-Ki Kim et al. NEURON
- Base editing rescue of spinal muscular atrophy in cells and in mice
- (2023) Mandana Arbab et al. SCIENCE
- Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS
- (2023) Paulos Gebrehiwet et al. JOURNAL OF MEDICAL ECONOMICS
- Infants with Congenital Diseases Identified through Newborn Screening—United States, 2018–2020
- (2023) Amy Gaviglio et al. International Journal of Neonatal Screening
- Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
- (2022) Heidemarie Kletzl et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study
- (2022) Ilaria Bitetti et al. GENE THERAPY
- Novel Use of Nusinersen as a Therapeutic Bridge to Onasemnogene Abeparvovec‐xioi in a Premature Neonate with Type 1 Spinal Muscular Atrophy
- (2022) Leah Ferrante et al. MUSCLE & NERVE
- Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
- (2022) Kevin A. Strauss et al. NATURE MEDICINE
- Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
- (2022) Kevin A. Strauss et al. NATURE MEDICINE
- Newborn Screening for Spinal Muscular Atrophy in New York State: Clinical Outcomes From the First 3 Years
- (2022) Bo Hoon Lee et al. NEUROLOGY
- Five patients with Spinal muscular atrophy-progressive myoclonic epilepsy (SMA-PME): a novel pathogenic variant, treatment and review of the literature
- (2022) Parvaneh Karimzadeh et al. NEUROMUSCULAR DISORDERS
- Neuromuscular denervation and deafferentation but not motor neuron death are disease features in the Smn2B/- mouse model of SMA
- (2022) Maria J. Carlini et al. PLoS One
- Improving Recognition of Treatable Rare Neuromuscular Disorders in Primary Care: A Pilot Feasibility Study
- (2022) Federica S. Ricci et al. Children-Basel
- Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial
- (2022) Riccardo Masson et al. LANCET NEUROLOGY
- SMN controls neuromuscular junction integrity through U7 snRNP
- (2022) Sarah Tisdale et al. Cell Reports
- A versatile toolkit for overcoming AAV immunity
- (2022) Xuefeng Li et al. Frontiers in Immunology
- California’s experience with SMA newborn screening: A successful path to early intervention
- (2022) Jamie Matteson et al. Journal of Neuromuscular Diseases
- Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis
- (2022) David Fox et al. ADVANCES IN THERAPY
- Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey
- (2022) Giorgia Coratti et al. NEUROLOGY
- Newbornscreening SMA – From Pilot Project to Nationwide Screening in Germany
- (2022) Wolfgang Müller-Felber et al. Journal of Neuromuscular Diseases
- Ancestral library identifies conserved reprogrammable liver motif on AAV capsid
- (2022) Eric Zinn et al. Cell Reports Medicine
- Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study
- (2021) Gyula Acsadi et al. MUSCLE & NERVE
- In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice
- (2021) Luke W. Koblan et al. NATURE
- Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
- (2021) Stacy A. Rudnicki et al. Neurotherapeutics
- Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines
- (2021) Hasane Ratni et al. ACS Medicinal Chemistry Letters
- A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
- (2021) Doreen Barrett et al. ADVANCES IN THERAPY
- Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
- (2021) John W Day et al. LANCET NEUROLOGY
- Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges
- (2021) Annarita Miccio et al. MOLECULAR THERAPY
- Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
- (2021) Jerry R. Mendell et al. JAMA Neurology
- Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
- (2021) Brian T. Welsh et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme
- (2021) Arlene M D'Silva et al. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
- Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function
- (2021) Scott E. Collibee et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
- (2021) Eugenio Mercuri et al. LANCET NEUROLOGY
- Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
- (2021) Eugenio Mercuri et al. LANCET NEUROLOGY
- Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue
- (2021) Gretchen Thomsen et al. NATURE MEDICINE
- Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
- (2021) Andrada Mirea et al. Journal of Clinical Medicine
- Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data
- (2020) Xiao Chen et al. GENETICS IN MEDICINE
- AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
- (2020) Helena Costa Verdera et al. MOLECULAR THERAPY
- ASAH1 pathogenic variants associated with acid ceramidase deficiency (ACD): Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy (SMA‐PME)
- (2020) Sarah H. Elsea et al. HUMAN MUTATION
- Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type I
- (2020) Amy G. Feldman et al. JOURNAL OF PEDIATRICS
- AAV9-Mediated Expression of SMN Restricted to Neurons Does Not Rescue the Spinal Muscular Atrophy Phenotype in Mice
- (2020) Aurore Besse et al. MOLECULAR THERAPY
- Variant effect on splicing regulatory elements, branchpoint usage, and pseudoexonization: Strategies to enhance bioinformatic prediction using hereditary cancer genes as exemplars
- (2020) Daffodil Canson et al. HUMAN MUTATION
- Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec
- (2020) Susan E. Matesanz et al. JOURNAL OF CHILD NEUROLOGY
- Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy
- (2020) Ali Jalali et al. JOURNAL OF PEDIATRICS
- Combination molecular therapies for type 1 spinal muscular atrophy
- (2020) Yohei Harada et al. MUSCLE & NERVE
- A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS
- (2020) Jeremy M. Shefner et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Current Clinical Applications of In Vivo Gene Therapy with AAVs
- (2020) Jerry R. Mendell et al. MOLECULAR THERAPY
- Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
- (2020) Deepa Chand et al. JOURNAL OF HEPATOLOGY
- Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
- (2019) Eloise Hudry et al. NEURON
- Nusinersen in later-onset spinal muscular atrophy
- (2019) Basil T. Darras et al. NEUROLOGY
- Impact of age and motor function in a phase 1/2A study of infants with SMA Type 1 receiving single-dose gene replacement therapy
- (2019) Linda P. Lowes et al. PEDIATRIC NEUROLOGY
- Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
- (2019) C. Frank Bennett et al. Annual Review of Neuroscience
- Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
- (2019) Darryl C. De Vivo et al. NEUROMUSCULAR DISORDERS
- The implementation of newborn screening for spinal muscular atrophy: the Australian experience
- (2019) Didu S. T. Kariyawasam et al. GENETICS IN MEDICINE
- Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy
- (2018) Alessandra Govoni et al. MOLECULAR NEUROBIOLOGY
- Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases
- (2018) Maite Calucho et al. NEUROMUSCULAR DISORDERS
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier
- (2018) Stefan Sturm et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy
- (2017) N N Singh et al. GENE THERAPY
- Implications of human genetic variation in CRISPR-based therapeutic genome editing
- (2017) David A Scott et al. NATURE MEDICINE
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review
- (2017) Ingrid E. C. Verhaart et al. Orphanet Journal of Rare Diseases
- Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers
- (2017) Manaswini Sivaramakrishnan et al. Nature Communications
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
- (2016) Richard S Finkel et al. LANCET
- Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector
- (2016) Sourav R Choudhury et al. MOLECULAR THERAPY
- Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
- (2016) Claudia A. Chiriboga et al. NEUROLOGY
- Adeno-Associated Virus at 50: A Golden Anniversary of Discovery, Research, and Gene Therapy Success—A Personal Perspective
- (2015) Eric Hastie et al. HUMAN GENE THERAPY
- Spinal Muscular Atrophy
- (2015) Stephen J. Kolb et al. NEUROLOGIC CLINICS
- Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies
- (2014) Kristien Peeters et al. BRAIN
- Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?
- (2013) Monir Shababi et al. JOURNAL OF ANATOMY
- Early heart failure in the SMNΔ7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery
- (2010) Adam K. Bevan et al. HUMAN MOLECULAR GENETICS
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice
- (2008) Yimin Hua et al. AMERICAN JOURNAL OF HUMAN GENETICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started